

Grifols collaborates with startup FcR Therapeutics to develop recombinant therapies for autoimmune diseases

- *Early stage R&D collaboration seeks to engineer recombinant biologics to block Fc receptors, key contributors to autoimmune diseases*
- *The initiative draws on Grifols' deep expertise in immunoglobulins and growing strength in the field of recombinant technologies*
- *Grifols continues to strengthen its robust innovation pipeline, diversified across early and late-stage initiatives spanning its core therapeutic areas*

Barcelona, Spain, Feb. 4, 2025 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that it is collaborating with a biotechnology startup, FcR Therapeutics, to develop recombinant nanobodies to treat autoimmune diseases.

The nanobodies, which are small highly specialized antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that play a crucial role in immune responses, such as driving inflammation or pathogen neutralization.

Grifols is helping seed the work of FcR Therapeutics, based in Utrecht, the Netherlands, in addition to contributing its vast knowledge of immunoglobulins, the human immune system and recombinant proteins.

Patients with autoimmune conditions have an overactive immune system in which certain Fc receptors facilitate attacks on the body's own healthy tissue. Suppressing their action can regulate excessive immune activity.

Immunoglobulins and their immunomodulatory effects normally help treat autoimmune diseases such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), immune thrombocytopenic purpura (ITP) and Guillain-Barré Syndrome (GBS).

“Grifols is excited to contribute its deepening knowledge of therapeutic antibody development, including recombinants, to FcR Therapeutics in its work to treat immune system disorders with unmet medical needs,” said Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer. “We continue to enhance our internal innovation portfolio, covering late- and early-stage projects across our core therapeutic areas, with complementary external capabilities to develop new treatments for patients.”

GRIFOLS

Grifols' collaboration with FcR Therapeutics is part of the company's ongoing commitment to innovation in the autoimmune disease therapeutic space.

"We are thrilled to collaborate with Grifols, enabling us to develop key therapeutics for autoimmune patients around the world," said Mark de Boer, CEO of FcR Therapeutics. "We believe that targeting Fc receptors through our nanobody approach will truly change the course of autoimmune diseases and transform the lives of patients."

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (Tel. + 34 659 572 185)

Borja_gomez@duomocomunicacion.com

Investors

Investors Relations & Sustainability

investors@grifols.com

Tel. +34 93 571 02 21

FcR Therapeutics

Mark de Boer

mark.deboer@fcrtherapeutics.com

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

GRIFOLS

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit grifols.com

About FcR Therapeutics

FcR Therapeutics is an innovative biotechnology startup based in Utrecht, The Netherlands, dedicated to advancing the understanding of Fc receptors and their role in autoimmune diseases. The company is pioneering the development of recombinant nanobody-based therapeutics aimed at selectively modulating Fc receptor activity to address the underlying mechanisms of autoimmune disorders.

With a focus on precision and innovation, FcR Therapeutics harnesses cutting-edge research in immunology and recombinant engineering to develop therapies that offer new hope to patients with unmet medical needs. The company's expertise in nanobody technology provides a novel approach to treating conditions where traditional therapies may fall short.

Committed to transforming the lives of patients, FcR Therapeutics collaborates with global leaders in healthcare, such as Grifols, to leverage synergies and accelerate the development of groundbreaking treatments for immune-mediated diseases.

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.